ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aclaris Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.48+0.20 (+6.10%)
Close on Oct 19, 2026
- Market cap
- $496.72M
- P/E (TTM)
- –
- Dividend yield
- –
Aclaris Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Aclaris Therapeutics | Industry median |
|---|---|---|
| Market Cap | $512.25M | $197.05M |
| Enterprise Value | $341.65M | $106.56M |
| PS Ratio | 62.33 | 3.93 |
| PB Ratio | 4.11 | 2.14 |
| P/TBV Ratio | 4.11 | 2.46 |
Enterprise value
| Measure | Aclaris Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 41.57 | 2.69 |
Income (trailing twelve months)
| Measure | Aclaris Therapeutics | Industry median |
|---|---|---|
| Revenue | $8.22M | $57.94M |
| Gross Profit | $6.54M | $90.47M |
| Operating Income | -$86.31M | -$21.44M |
| Net Income | -$75.74M | -$22.46M |
| EBITDA | -$85.89M | -$16.91M |
| EPS (Diluted) | -$0.58 | -$0.83 |
Margins
| Measure | Aclaris Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 79.5% | 52.3% |
| Operating Margin | -1050.2% | -44.5% |
| Profit Margin | -921.5% | -39.2% |
| EBITDA Margin | -1045.0% | -31.3% |
| FCF Margin | -756.5% | -8.85% |
Returns
| Measure | Aclaris Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -59.1% | -53.1% |
| Return on Assets (ROA) | -41.1% | -41.0% |
| Return on Capital Employed (ROCE) | -57.0% | -37.8% |
Growth
| Measure | Aclaris Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -51.0% | 6.01% |
| Revenue Growth (3Y CAGR) | -35.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 3.84% | 6.42% |
Balance sheet
| Measure | Aclaris Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $170.60M | $62.42M |
| Net Cash (Debt) | $170.60M | $15.68M |
| Net Cash Per Share | $1.16 | $0.65 |
| Equity (Book Value) | $124.58M | $48.79M |
| Book Value Per Share | $0.85 | $1.36 |
| Tangible Book Value | $124.58M | $23.06M |
| Working Capital | $69.52M | $75.77M |
Financial position
| Measure | Aclaris Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 3.46 | 3.30 |
| Quick Ratio | 6.04 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Aclaris Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$62.06M | -$12.35M |
| Capital Expenditures | -$118.00K | -$1.06M |
| Free Cash Flow | -$62.18M | -$20.28M |
| FCF Per Share | -$0.42 | -$0.41 |
Efficiency
| Measure | Aclaris Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.04 | 0.38 |
| Revenue Per Employee | $112.59K | $398.96K |
| Profits Per Employee | -$1.04M | -$732.08K |
| Employee Count | 73 | 73 |
Dividends and yields
| Measure | Aclaris Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -14.8% | -21.2% |
| FCF Yield | -12.1% | -7.64% |
Shares
| Measure | Aclaris Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 147,199,000 | 59,128,900 |
| Shares Change (YoY) | 25.5% | 11.1% |
| Shares Change (QoQ) | 0.12% | 0.54% |
| Float | 127,675,000 | 48,744,500 |
| Shares Held by Insiders | 13.3% | 11.8% |
| Shares Held by Institutions | 82.3% | 59.4% |
Scores
| Measure | Aclaris Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -3.36 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Aclaris Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.